AstraZeneca PLC’s anti-interleukin-13 (IL-13) human monoclonal antibody tralokinumab has failed in two further Phase III studies (STRATOS 2 and TROPOS), leaving the company now banking on benralizumab to help offset generic pressure to its asthma franchise.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?